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Background
Previous studies in adoptive T-cell transfer have suggested
that persistence of the transduced T-cells is central to
making this therapy a viable option. Understanding the
behavior of tumor-reactive T-cells in cancer patients and
measuring persistence are two objectives in a phase I clini-
cal trial using TCR TIL 1383I transduced T cells in stage
IV melanoma patients.
Methods
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from a melanoma patient, activated with anti-
hCD3 with rhIL2 and rhIL15, transduced with lentivirus
encoding the TIL 1383I TCR, and expanded to treat-
ment numbers. 2 x 108 transduced cells were suspended
in 5% human albumin and infused over 30 minutes. The
infusion was preceded by lymphodepletion with fludara-
bine and cyclophosphomide and followed with low dose
IL-2 for one week. A modified CD34 cassette in the
vector enabled monitoring of the transduced T cells in
the patient’s PBMC post-infusion. PBMC were collected
from patient on days 1, 3, 5, 7, 14, 25, and 35. The pre-
sence of transduced T cells at each timepoint was mea-
sured by staining with anti-CD34 mAb and analyzed
using a BD LSRFortessa flow cytometer.
Results
Transduced T cells were detected in the patient’s blood
at day 25 post infusion. 1.45% of the patients T cells
were TIL 1383I TCR transduced T-cells. We estimate
that at least 10% of the infused TIL 1383I TCR trans-
duced T cells were present after 4 weeks.
Conclusion
Previous studies with TIL suggest better T-cell engraft-
ment, persistence, and therapeutic efficacy with homeo-
static proliferation after lymphodepletion. Out results
confirm that the infused TIL 1383I TCR transduced
T-cells could be detected 4 weeks after infusion. Locali-
zation of genetically engineered T-cells and ensuring
their activation and function is of value in anti-tumor
T-cell therapy.
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